[1]周超飞 郭毅 邓珏琳.H型高血压与心房颤动的关系研究进展[J].心血管病学进展,2019,(9):1205-1207.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.005]
　ZHOU ChaofeiGUO YiDENG Juelin.H-type Hypertension and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(9):1205-1207.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.005]
点击复制

H型高血压与心房颤动的关系研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年9期
页码:
1205-1207
栏目:
主题综述
出版日期:
2019-12-25

文章信息/Info

Title:
H-type Hypertension and Atrial Fibrillation
作者:
周超飞 郭毅 邓珏琳
(解放军总医院海南医院,海南 三亚 572003 )
Author(s):
ZHOU ChaofeiGUO YiDENG Juelin
(Hainan Hospital of PLA General HospitalSanya 572003HainanChina)
关键词:
心房颤动; 高血压; 高同型半胱氨酸血症
Keywords:
Atrial fibrillation;  Hypertension; Hyperhomocysteinemia
DOI:
10.16806/j.cnki.issn.1004-3934.2019.09.005
摘要:
心房颤动是临床常见的心律失常之一，与高血压常常同时存在，高血压患者合并高同型半胱氨酸血症称为H型高血压，H型高血压与心房颤动的病理生理机制越来越受到更多临床医生的关注。血清高同型半胱氨酸水平与心房颤动和高血压的发生、发展和预后相关，治疗高同型半胱氨酸血症对高血压及心房颤动的治疗有协同作用。
Abstract:
Atrial fibrillation (AF) is one of the common arrhythmias in clinical practice, which often exists together with hypertension. Patients with hypertension combined with hyperhomocysteinemia are called h-type hypertension. The pathophysiological mechanism of h-type hypertension and atrial fibrillation has been attracted more attention by clinicians. The level of hyperhomocysteinemia is associated with the occurrence, development and prognosis of atrial fibrillation and hypertension. The administration of hyperhomocysteinemia has synergistic effects on the treatment of hypertension and atrial fibrillation.

参考文献/References:

[1].Xu H,Zheng H,Huang J,et al. T-cell subsets are associated with serum homocysteine concentration in patients with essential hypertensio n[J]. Clin Exp Hypertens ,2017,39(4):377-381.
[2].姜雪,王建凤.高血压与心房颤动[J].心血管病学进展,2014, 35(2):149-152.
[3].Conen D, Tedrow UB, Koplan BA,et al.Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women[J]. Circulation ,2009, 119(16): 2146-2152.
[4].Grundvold I, Skretteberg PT, Liest?l K,et al.Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study[J]. Hypertension,2012,59(2):198-204.
[5].. Pathak RK, Middeldorp ME, Lau DH,et al.Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study[J]. J Am Coll Cardiol,2014,2(64):2222-2231.
[6].Chatterjee S, Bavishi C, Sardar P,et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias[J]. Am J Cardiol,2014, 1(114): 1049-1052.
[7].Manolis AJ, Poulimenos LE, Kallistratos MS,et al.Sympathetic overactivity in hypertension and cardiovascular disease[J]. Curr Vasc Pharmacol,2014,12(1):4-15.
[8].Manolis AJ, Kallistratos MS, Poulimenos LE,et al. Recent clinical trials in atrial fibrillation in hypertensive patients[J]. Curr Hypertens Rep ,2012,14(4): 350-359.
[9].温改艳,袁洪,舒婧娴,等.抗高血压药物的研究现状[J].中国临床药理学杂志,2017,33(24):2629-2632.
[10].Zhou Y,Zhao L,Zhang Z,et al. Protective effect of enalapril against methionine-enriched diet-induced?hypertension: role of endoplasmic reticulum and oxidative stress[J].Biomed Res Int,2015,2015: 724876-724882.
[11].Han L,Wu Q,Wang C,et al.Homocysteine, ischemic stroke and coronary heart disease in hypertensive patients:a population-based, prospective cohort study[J]. Stroke,2015,46(7):1777-1786.
[12].Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke[J].JAMA,2002, 288:2015-2022.
[13].Shi Z,Guan Y,Huo YR,et al.Elevated total homocysteine levels in acute ischemic stroke are associated with long-term mortality[J].Stroke,2015,46(9): 2419-2425.
[14].Yao Y,Yao W,Bai R,et al. Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation[J]. Europace,2017, 19(1): 66-71.
[15].王雅坤,师聪红,王娟,等.同型半胱氨酸与高血压合并房颤患者的研究[J].临床医药文献电子杂志,2017,4(52):10104-10105,10107.
[16].Yao Y,Gao LJ,Zhou Y,et al.Effect of advanced age on plasma?homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation[J]. J Geriatr Cardiol,2017,14(12):743-749.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(9):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(9):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
　SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(9):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[6]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[7]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[8]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
　FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(9):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[9]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[10]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(9):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[11]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
　SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[12]李英  刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
　LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(9):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[13]任艳霞 郭雪娅.高血压与心房颤动的关系[J].心血管病学进展,2021,(3):240.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.012]
　REN Yanxia,GUO Xueya.Hypertension and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):240.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.012]

更新日期/Last Update: 2020-02-06